Novo Nordisk (NVO) said that it has decided to enter phase 3a development in obesity with oral semaglutide 50 mg.
The move comes following the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous semaglutide 2.4 mg.
The company plans to initiate a pivotal phase 3a program with about 1,000 people with obesity or overweight with comorbidities.
The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.